Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380276 · ClinicalTrials.gov registry record · Phase 3
Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
A Phase 3 study, sponsored by Myrexis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
NCT00380276: Clinical Trial Phase 3 study, sponsored by Myrexis.
NCT00380276 is a Phase 3 study that was terminated before completion, run by Myrexis. The registered enrollment target is 1,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00380276, a Phase 3 study, was terminated before completion, sponsored by Myrexis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
Open-label treatment with MPC-7869 for participants in a previous randomized study.
Interventions
- DRUG MPC-7869
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Why NCT00380276 stopped before completion
NCT00380276 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 1 intervention - of which MPC-7869 is the first listed.
NCT00380276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00380276 about?
NCT00380276 is a clinical study titled "Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol". Open-label treatment with MPC-7869 for participants in a previous randomized study.
What is the current status of trial NCT00380276?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2006-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00380276?
The interventions under investigation include: MPC-7869 (DRUG).
Who is sponsoring clinical trial NCT00380276?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00380276's enrollment target sits among peer trials
1,000 296th of 2000 higher than 1,689 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia